Tocqueville Asset Management L.P. Has $21.19 Million Stake in Medtronic PLC $MDT

Tocqueville Asset Management L.P. boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 3.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 222,513 shares of the medical technology company’s stock after buying an additional 8,268 shares during the period. Tocqueville Asset Management L.P.’s holdings in Medtronic were worth $21,192,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Artisan Partners Limited Partnership grew its stake in shares of Medtronic by 2.6% in the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after buying an additional 31,314 shares in the last quarter. AXQ Capital LP grew its position in shares of Medtronic by 25.6% in the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after purchasing an additional 2,013 shares during the last quarter. UMB Bank n.a. increased its position in Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares during the period. Applied Finance Capital Management LLC bought a new position in Medtronic during the third quarter worth about $1,308,000. Finally, Willis Investment Counsel raised its position in shares of Medtronic by 5.0% in the third quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after buying an additional 19,192 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Up 0.4%

MDT stock traded up $0.34 during midday trading on Friday, reaching $87.72. 1,276,342 shares of the company’s stock traded hands, compared to its average volume of 8,459,984. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a market cap of $112.62 billion, a price-to-earnings ratio of 24.43, a P/E/G ratio of 2.28 and a beta of 0.71. The firm’s fifty day moving average price is $98.14 and its 200-day moving average price is $96.87.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter last year, the firm earned $1.38 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Barclays reaffirmed an “overweight” rating and set a $118.00 price objective on shares of Medtronic in a research report on Wednesday, February 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $120.00 target price on shares of Medtronic in a report on Tuesday. Sanford C. Bernstein raised their price target on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday, March 1st. Finally, Wells Fargo & Company began coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).